Bacil Pharma (524516) Q3 25/26 earnings summary

Executive summary

• Unaudited financial results for the quarter and nine months ended December 31, 2025, were approved and reviewed by the Board and auditors on February 13, 2026.

• Statutory auditors issued an unmodified review report, confirming no material misstatements in the financials.

Financial highlights

• Revenue from operations for the quarter ended December 31, 2025, was ₹6.45 lakhs, compared to ₹5.49 lakhs in the previous quarter and ₹0.30 lakhs in the same quarter last year.

• Total expenses for the quarter were ₹2.53 lakhs, down from ₹3.65 lakhs in the previous quarter and ₹6.50 lakhs in the same quarter last year.

• Profit before tax for the quarter was ₹3.92 lakhs, compared to ₹1.84 lakhs in the previous quarter and a loss of ₹6.20 lakhs in the same quarter last year.

• Net profit after tax for the quarter was ₹3.92 lakhs, up from ₹1.38 lakhs in the previous quarter and a loss of ₹6.20 lakhs in the same quarter last year.

• Earnings per share (EPS) for the quarter was ₹0.03, compared to ₹0.01 in the previous quarter and a loss of ₹1.00 in the same quarter last year.

Key financial ratios and metrics

• Paid-up equity share capital stood at ₹1,397.03 lakhs as of December 31, 2025.

• Other comprehensive income for the quarter was ₹2.18 lakhs.